Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide

16 Jun 2026

Hyderabad, June 16, 2026:Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment to operating responsibly. Securing the EcoVadis Platinum Rating reflects the standards we have set for ourselves and the choices we have made over the years to build a resilient, future-ready organization.”

EcoVadis is among the world's most widely recognized sustainability ratings providers, assessing companies across Environment, Labour & Human Rights, Ethics, and Sustainable Procurement. 

The recognition reflects sustained progress across all four EcoVadis assessment pillars. Alongside its environmental initiatives - including a 100% renewable-powered manufacturing site, significant reductions in freshwater dependency, and investments in ecosystem restoration - Sai Life Sciences has strengthened its Labour & Human Rights practices through SA8000 certification and alignment with living wage principles. The company has also enhanced governance through board-level oversight of sustainability and ethics, while reinforcing responsible procurement through supplier assessments and ISO 28000-certified supply chain security practices.

The EcoVadis Platinum Rating builds on Sai Life Sciences' broader sustainability commitments and progress. In 2023, the company joined the Science Based Targets initiative (SBTi), committing to ambitious, science-based greenhouse gas reduction targets across its operations and value chain. In 2020, it became the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI) membership. Through initiatives such as its partnership with DHL GoGreen to reduce logistics-related emissions and value-chain engagement, Sai Life Sciences continues to advance a sustainability agenda focused on measurable impact, accountability, and long-term value creation.

Related News

Sai Life Sciences Limited sustains growth momentum in Q2FY26

Revenue up by 36%; EBITDA up by 43%; Net Profit up by 100% Hyderabad, November 06, 2025: Sai Life Sciences […]

7 Nov 2025

Where Nature Inspires Innovation: University of Kansas Prof. Apurba Dutta visits Sai

Dr. Apurba Dutta, Associate Professor at Department of Medicinal Chemistry, University of Kansas, USA, recently visited our Sai Life Sciences […]

5 Nov 2025

Sai Life Sciences becomes a signatory to the UN Women’s Empowerment Principles

Sai Life Sciences has joined the global community of signatories to the Women’s Empowerment Principles (WEPs) — an initiative established […]

31 Oct 2025
8 / 45 FirstPrevious678910Next Last

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Corporate Policies
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube